Recombinant Bovine Somatotropin vs Neotame: which is worse?
Quick answer: Recombinant Bovine Somatotropin carries the heavier risk profile. Recombinant Bovine Somatotropin is — in the EU and — in the US; Neotame is — in the EU and — in the US.
| Property | Recombinant Bovine Somatotropin | Neotame |
|---|---|---|
| EU status | — | — |
| US status | — | — |
| Risk level | — | — |
| Banned in | European Union, Canada, Japan, Australia, New Zealand | — |
| Restricted in | — | European Union (ADI 2 mg/kg body weight), Australia, Canada |
| Category | additive | additive |
| Where it hides | — | — |
What is Recombinant Bovine Somatotropin?
Recombinant bovine somatotropin (rBST) is the synthetic version of bovine growth hormone (BST), naturally produced by the pituitary gland in cattle. The recombinant version is produced using genetically engineered bacteria and is injected into dairy cows to increase milk production by 10-15%. Brand name: Posilac.
What is Neotame?
Neotame is a synthetic dipeptide sweetener — a derivative of aspartame with a 3,3-dimethylbutyl group added to block aspartame's metabolism, preventing the release of phenylalanine. This means it is safe for people with phenylketonuria (PKU), unlike aspartame. It is approximately 7,000-13,000 times sweeter than sucrose.
Documented risks
Recombinant Bovine Somatotropin: See recombinant-bovine-growth-hormone-rbgh for full detail. Key concerns: rBST elevates IGF-1 in milk; elevated blood IGF-1 is associated with breast, prostate, and colorectal cancer risk in epidemiological studies. Animal welfare: increased mastitis (up to 25-50% higher rates), lameness, and antibiotic use. The Codex Alimentarius Commission declined to endorse rBST safety MRLs in a historic 33-29 vote. Health Canada rejected rBST approval in 1999 after finding it caused significant animal health problems requiring increased antibiotic use.
Neotame: Neotame is one of the newer synthetic sweeteners with a shorter safety track record. A 2023 study published in Frontiers in Nutrition found that neotame damaged intestinal epithelial cells in vitro and disrupted the gut microbiome in mice — including reducing beneficial bacteria and increasing bacterial invasion of intestinal cells. The study observed effects at concentrations that could be achievable through high consumption of neotame-containing products. The FDA has set an ADI of 0.3 mg/kg/day, one of the lower sweetener ADIs, reflecting a conservative safety margin. Limited long-term human safety data exist compared to aspartame, acesulfame K, or saccharin, which have been used for decades. EFSA's 2010 opinion found no safety concern at permitted levels. The Frontiers in Nutrition 2023 gut study represents new concerning findings that warrant further investigation.
Scan a barcode and we'll flag both Recombinant Bovine Somatotropin and Neotame (plus 200+ other ingredients banned overseas).
Scan free →